Mesenchymal stem cell-derived exosome subpopulations remained consistent for 28 culture days, displaying therapeutic effects in a silicosis mouse model DOI Creative Commons
Lina Zhang, Jing Jin, Liguang Sun

и другие.

Frontiers in Cell and Developmental Biology, Год журнала: 2025, Номер 13

Опубликована: Май 27, 2025

Introduction The clinical translation of mesenchymal stem cell-derived exosome faces critical challenges in scalable production, subpopulation stability, and therapeutic route optimization. This study systematically addresses these barriers to advance exosome-based therapies. Methods We established a 28-day biomanufacturing workflow using Hollow Fiber 3D bioreactor integrated with the RoosterBio exosome-harvesting system. Exosomes were subsequently purified rigorously characterized at multiple production stages, followed by isotopically labeled 89 Zr for biodistribution studies. Therapeutic efficacy was evaluated silica-induced mouse silicosis model comparing intravenous respiratory administration routes. Results Our findings indicate that (1) harvesting system enables 28 days exosomes, stable main subpopulations over certain period; (2) systemic via injection rats reveals distinct tissue tropism, isotope-labeled exosomes exhibiting predominant hepatic accumulation; (3) model, delivery significantly improves disease progression, whereas infusion does not yield notable effects. Discussion proposes holistic early-stage development natural as therapeutics, offering guidance on industrial-scale purification, characterization distribution functional consistency. It further selection pulmonary animal models heterogeneity assessment exosomes. These advancements facilitate

Язык: Английский

Mesenchymal stem cell-derived exosome subpopulations remained consistent for 28 culture days, displaying therapeutic effects in a silicosis mouse model DOI Creative Commons
Lina Zhang, Jing Jin, Liguang Sun

и другие.

Frontiers in Cell and Developmental Biology, Год журнала: 2025, Номер 13

Опубликована: Май 27, 2025

Introduction The clinical translation of mesenchymal stem cell-derived exosome faces critical challenges in scalable production, subpopulation stability, and therapeutic route optimization. This study systematically addresses these barriers to advance exosome-based therapies. Methods We established a 28-day biomanufacturing workflow using Hollow Fiber 3D bioreactor integrated with the RoosterBio exosome-harvesting system. Exosomes were subsequently purified rigorously characterized at multiple production stages, followed by isotopically labeled 89 Zr for biodistribution studies. Therapeutic efficacy was evaluated silica-induced mouse silicosis model comparing intravenous respiratory administration routes. Results Our findings indicate that (1) harvesting system enables 28 days exosomes, stable main subpopulations over certain period; (2) systemic via injection rats reveals distinct tissue tropism, isotope-labeled exosomes exhibiting predominant hepatic accumulation; (3) model, delivery significantly improves disease progression, whereas infusion does not yield notable effects. Discussion proposes holistic early-stage development natural as therapeutics, offering guidance on industrial-scale purification, characterization distribution functional consistency. It further selection pulmonary animal models heterogeneity assessment exosomes. These advancements facilitate

Язык: Английский

Процитировано

0